Drugs / VRC-FLUMOS0116-00-VP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06863142 | Apr 2025 → Jul 2026 overdue | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT05968989 | Aug 2023 → Nov 2025 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-FLUMOS0116-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06863142 ↗ |
| Known as | FluMos-v2 | “The VRC-FLUMOS0116-00-VP (FluMos-v2) vaccine is composed of de novo engineered pentamer assembled with de novo engineered trimeric domains to an icosahedral core, projecting 20...” NCT06863142 ↗1“VRC-FLUMOS0116-00-VP( FLUMos-v2)” NCT05968989 ↗ |
| Modality | Vaccine | “mosaic hexavalent influenza vaccine” NCT05968989 ↗ |
| Route | Intramuscular | “will be administered intramuscularly (IM)” NCT05968989 ↗ |